Nausea is the most common GI effect in GLP-1 studies. The cause is pharmacodynamics — delayed gastric emptying, not 'poisoning'.
GLP-1 agonists slow gastric emptying and act on brainstem vomiting centers. That is why the effect is dose-dependent and intensifies during titration.
Start at minimum dose, step every few weeks.
Smaller volume, less fat — in the context of studied protocols.
Fluid deficit amplifies nausea.
Not medical advice — a summary of published data.
Published data suggest easing within a few weeks at a stable dose.